Health and Social Care Committee
HSC(4)-15-12 paper 3
One-day inquiry into venous thrombo-embolism prevention
– Evidence from Royal College of Obstetricians and Gynaecologists
Transforming Maternity Services Mini-Collaborative
Venous Thromboembolism (VTE)
Obstetric All Wales DVT Risk Assessment
Part of 1000 Lives Plus, the overall aim of the Transforming Maternity Services Mini-Collaborative is to improve the experience and outcomes for women, babies and their families within Maternity Services. One of the drivers in achieving this aim is to reduce the risk of venous thromboembolism in pregnancy.
Implementation of interventions relating to deep venous thrombosis (DVT) risk assessment should have been straight forward, because the Royal College of Obstetricians and Gynaecologists had published an evidenced based ‘green-top guideline’ on this subject. Although the guideline summarises the known increased risks of VTE in pregnancy, application of this knowledge to routine pregnancies creates an additional risk of increased morbidity and caesarean section. The level of the evidence has been queried in clinical practice, with the result that there was limited and inconsistent risk assessment taking place in maternity units in Wales.
The Transforming Maternity Services Mini-Collaborative brings together experts, clinicians and managers to effect change at the bedside (from the ‘bottom up’). It is endorsed by Welsh Government, all Health Boards in Wales, and the Royal Colleges of Midwives (RCM), and Obstetricians and Gynaecologists (RCOG) in Wales.
The multi-disciplinary and inter-professional nature of the mini-collaborative has seen discussion by maternity staff in Wales with the aim of producing clarity in VTE risk assessment in pregnancy. Feedback from the service demonstrated consensus among clinical staff that the RCOG Green top guideline had several drawbacks, as it may be thought of as ‘medicalising’ women who would be otherwise regarded as normal. It recommends thromboprophylaxis with low molecular weight heparin (LMWH) for women with a BMI that would result in over 1:4 needing to inject themselves with LMWH during or after pregnancy, for an uncertain benefit, based on trial evidence that is of relatively low quality. There are no data on the clinical or cost-effectiveness of such a strategy.
Following consultation with experts from within Wales and the relevant endorsement committees, consensus has been reached to enable universal VTE risk assessment to be implemented throughout Wales, with two Exemplar DVT Risk Assessment Templates – one relating to the initial ‘Booking’ visit, which is to be included in the National Hand-Held records and one relating to Antenatal Admission and the puerperium (postnatal period). This has been a significant achievement for the mini-collaborative in a short period of time and is now allowing maternity units to proceed with implementation of the bundles.
All Health boards within Wales are currently implementing these risk assessments following localisation and agreement within their scrutiny committees.
It is recommended that DVT Risk Assessment be carried for pregnant women firstly at their booking appointment (ideally by 12 weeks pregnancy), at each antenatal admission and again following the birth.
Work is also underway to implement a combined antenatal booking and admission risk assessment within gynaecological wards alongside the general DVT risk assessment.
Below are the agreed risk assessments:
Deep Vein Thrombosis Risk Assessment Booking All women to be assessed by midwife at first/booking appointment. |
||||||||||||||||||||||||||||||||||||||||||||||
Indications for consideration of antenatal thromboprophylaxis
Please refer to local guidance re referral timeframes and follow-up.
This assessment needs to form part of any further risk assessment following identification of risk factors (and referral) or during any AN hospital admission.
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ANTENATAL ADMISSION Indications for thromboprophylaxis (TEDS & Clexane) whilst antenatal inpatient. Indication : One identified indication = Thromboprophylaxis to be considered
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prescription of Thromboprophylaxis:
Prescribe according to booking weight unless there has been a significant weight gain during the pregnancy of >12kg |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weight (kg) |
Enoxaparin dose (mg) |
frequency |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
<50 |
20 |
od |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
50-100 |
40 |
od |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
101-120 |
40 |
bd |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
>120 |
60 |
bd |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contraindications to Enoxaparin (CLEXANE)
|
|
Ensure thromboprophylaxis (TEDS & Clexane for 5 days) has been prescribed following birth with one or more factor |
Yes |
No |
Women receiving thromboprophylaxis during pregnancy should continue treatment for 6 weeks postpartum |
PPH >1500ml |
|
|
|
Red blood cell transfusion or transfusion of coagulation factors |
|
|
|
Caesarean section (elective or emergency) |
|
|
|
Still-birth |
|
|
|
BMI >40kg/m2 |
|
|
Signature
Date |
Sepsis |
|
|
|
Complex vaginal delivery (Consider thromboprophylaxis) |
|
|
|
Thromboprophylaxis required |
|
|
|
Delay commencement until 6 hours following epidural catheter removal or completion of spinal anaesthesia. Encourage early mobilisation, hydration and awareness of symptoms of VTE in all women. |
|||
Prescription of postnatal Thromboprophylaxis: As table above. To be calculated using booking weight. |